.. Rôle-des-plaquettes-dans-l-'hémostase, 52 I-E.1.2.1. Amplification : recrutement et activation précoce des plaquettes, p.52

F. De and F. De, 60 I-F.2. Signaux de danger liés à l'environnement généré par l'administration, p.60

S. Ehrenforth, W. Kreuz, I. Scharrer, R. Linde, M. Funk et al., Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs, The Lancet, vol.339, issue.8793, pp.594-602, 1992.
DOI : 10.1016/0140-6736(92)90874-3

J. Astermark, Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia, Haemophilia, vol.84, issue.9, pp.52-60, 2006.
DOI : 10.1046/j.1365-2516.1999.00343.x

J. Skupsky, A. Zhang, Y. Su, and D. Scott, A role for thrombin in the initiation of the immune response to therapeutic factor VIII, Blood, vol.114, issue.21, pp.4741-4749, 2009.
DOI : 10.1182/blood-2008-10-186452

V. Factor, N. Structure, and . Activity, Is the Primary Determinant of Immunogenicity in Hemophilia A and Combined Hemophilia A/Von Willebrand Disease Mice, 53rd ASH Annual Meeting and exposition, 2011.

T. Kawai and S. Akira, Toll-like Receptors and Their Crosstalk with Other Innate Receptors in Infection and Immunity, Immunity, vol.34, issue.5, pp.637-50, 2011.
DOI : 10.1016/j.immuni.2011.05.006

R. Medzhitov, C. Janeway, and J. , The Toll receptor family and microbial recognition, Trends in Microbiology, vol.8, issue.10, pp.452-458, 2000.
DOI : 10.1016/S0966-842X(00)01845-X

S. Akira and K. Takeda, Toll-like receptor signalling, Nature Reviews Immunology, vol.303, issue.7, pp.499-511, 2004.
DOI : 10.1038/nri1391

J. Kang, X. Nan, M. Jin, S. Youn, Y. Ryu et al., Recognition of Lipopeptide Patterns by Toll-like Receptor 2-Toll-like Receptor 6 Heterodimer, Immunity, vol.31, issue.6, pp.873-84, 2009.
DOI : 10.1016/j.immuni.2009.09.018

S. Amith, The role of NEU1sialidase in toll-like receptor activation. Department of Microbiology and Immunology, p.299, 2009.

L. Hoyer and A. Hemophilia, Hemophilia A, New England Journal of Medicine, vol.330, issue.1, pp.38-47, 1994.
DOI : 10.1056/NEJM199401063300108

E. Davie, K. Fujikawa, and W. Kisiel, The coagulation cascade: initiation, maintenance, and regulation, Biochemistry, vol.30, issue.43, pp.10363-10370, 1991.
DOI : 10.1021/bi00107a001

J. Oldenburg and A. Pavlova, Genetic risk factors for inhibitors to factors VIII and IX, Haemophilia, vol.77, issue.1, pp.15-22, 2006.
DOI : 10.1016/0167-5699(92)90107-I

S. Dasgupta, A. Navarrete, and J. Bayry, A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+ T lymphocytes, Proceedings of the National Academy of Sciences, vol.104, issue.21, pp.8965-8970, 2007.
DOI : 10.1073/pnas.0702120104

S. Dasgupta, Y. Repesse, and J. Bayry, VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors, Blood, vol.109, issue.2, pp.610-612, 2007.
DOI : 10.1182/blood-2006-05-022756

S. Delignat, Y. Repesse, and A. Navarrete, Immunoprotective effect of von Willebrand factor towards therapeutic factor VIII in experimental haemophilia A, Haemophilia, vol.117, issue.2, pp.248-254, 2012.
DOI : 10.1111/j.1365-2516.2011.02679.x

A. Wroblewska, S. Van-haren, and E. Herczenik, Modification of an exposed loop in the C1 domain reduces immune responses to factor VIII in hemophilia A mice, Blood, vol.119, issue.22, pp.5294-5300, 2012.
DOI : 10.1182/blood-2011-11-391680

G. Davi and C. Patrono, Platelet Activation and Atherothrombosis, New England Journal of Medicine, vol.357, issue.24, pp.2482-2494, 2007.
DOI : 10.1056/NEJMra071014

J. Skupsky, A. Zhang, Y. Su, and D. Scott, A role for thrombin in the initiation of the immune response to therapeutic factor VIII, Blood, vol.114, issue.21, pp.4741-4748, 2009.
DOI : 10.1182/blood-2008-10-186452

S. Meeks, C. Cox, and J. Healey, A major determinant of the immunogenicity of factor VIII in a murine model is independent of its procoagulant function, Blood, vol.120, issue.12, 2012.
DOI : 10.1182/blood-2012-02-412361

J. George, Platelets, The Lancet, vol.355, issue.9214, pp.1531-1539, 2000.
DOI : 10.1016/S0140-6736(00)02175-9

URL : https://hal.archives-ouvertes.fr/hal-01455290

M. Cattaneo, A. Lecchi, A. Randi, J. Mcgregor, and P. Mannucci, Identification of a new congenital defect of platelet function characterized by severe impairment of platelet responses to adenosine diphosphate, Blood, vol.80, issue.11, pp.2787-2796, 1992.

E. Boilard, P. Nigrovic, and K. Larabee, Platelets Amplify Inflammation in Arthritis via Collagen-Dependent Microparticle Production, Science, vol.327, issue.5965, pp.580-583, 2010.
DOI : 10.1126/science.1181928

A. Solanilla, J. Pasquet, and J. Viallard, Platelet-associated CD154 in immune thrombocytopenic purpura, Blood, vol.105, issue.1, pp.215-218, 2005.
DOI : 10.1182/blood-2003-07-2367

URL : https://hal.archives-ouvertes.fr/hal-00019938

G. Cirino, C. Cicala, M. Bucci, L. Sorrentino, J. Maraganore et al., Thrombin functions as an inflammatory mediator through activation of its receptor, Journal of Experimental Medicine, vol.183, issue.3, pp.821-827, 1996.
DOI : 10.1084/jem.183.3.821

S. Coughlin, Thrombin signalling and protease-activated receptors, Nature, vol.407, issue.6801, pp.258-264, 2000.
DOI : 10.1038/35025229

Y. Park, Y. J. Zhang, H. Chen, X. Zhang, and C. , Effect of PAR2 in regulating TNF-?? and NAD(P)H oxidase in coronary arterioles in type 2 diabetic mice, Basic Research in Cardiology, vol.297, issue.1, pp.111-123, 2011.
DOI : 10.1007/s00395-010-0129-9

M. Nakanishi-matsui, Y. Zheng, D. Sulciner, E. Weiss, M. Ludeman et al., PAR3 is a cofactor for PAR4 activation by thrombin, Nature, vol.404, issue.6778, pp.609-613, 2000.

M. Adams, R. Ramachandran, and M. Yau, Structure, function and pathophysiology of protease activated receptors, Pharmacology & Therapeutics, vol.130, issue.3, pp.248-282, 2011.
DOI : 10.1016/j.pharmthera.2011.01.003

E. Van-bladel, M. Roest, P. De-groot, and R. Schutgens, Up-regulation of platelet activation in hemophilia A, Haematologica, vol.96, issue.6, pp.888-895, 2011.
DOI : 10.3324/haematol.2011.042663

M. Teyssandier, S. Delignat, and J. Rayes, Activation state of platelet in experimental severe hemophilia A. Haematologica, 2012.

X. Nguyen, J. Muller-berghaus, T. Kalsch, D. Schadendorf, M. Borggrefe et al., Differentiation of monocyte-derived dendritic cells under the influence of platelets, Cytotherapy, vol.10, issue.7
DOI : 10.1080/14653240802378912

A. Weyrich, M. Elstad, and R. Mcever, Activated platelets signal chemokine synthesis by human monocytes., Journal of Clinical Investigation, vol.97, issue.6, pp.1525-1534, 1996.
DOI : 10.1172/JCI118575

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC507213

M. Nesheim, D. Pittman, and A. Giles, The effect of plasma von Willebrand factor on the binding of human factor VIII to thrombin-activated human platelets, J Biol Chem, vol.266, pp.17815-17826, 1991.

P. J. Lenting, J. A. Van-mourik, and K. Mertens, The life cycle of coagulation factor VIII in view of its structure and function, Blood, issue.11, pp.92-3983, 1998.

L. W. Hoyer and A. Hemophilia, Hemophilia A, New England Journal of Medicine, vol.330, issue.1, pp.38-47, 1994.
DOI : 10.1056/NEJM199401063300108

F. Daniele, V. Rossi, and C. Santoro, Effective management of intracranial haemorrhage with continuous infusion of highly purified von Willebrand factor/factor VIII complex concentrate in an adult with severe haemophilia A, Blood Transfus, vol.9, issue.4, pp.472-476, 2011.

S. E. Antonarakis, Molecular etiology of factor VIII deficiency in hemophilia A

G. I. Ingram, The history of haemophilia., Journal of Clinical Pathology, vol.29, issue.6, pp.469-79, 1976.
DOI : 10.1136/jcp.29.6.469

J. C. Otto, An account of an haemorrhagic disposition existing in certain families, Med. Repos, pp.1-4, 1828.

F. Hopff, J. G. Pool, E. J. Gershgold, and A. R. Pappenhagen, Über die Hämophilie oder die erbliche Anlage zu tödlichen Blutungen, High-Potency Antihaemophilic Factor Concentrate Prepared from Cryoglobulin Precipitate. Nature, p.312, 1828.

J. Gitschier, Characterization of the human factor VIII gene, Nature, vol.196, issue.5992, pp.312-326, 1984.
DOI : 10.1038/312326a0

J. Oldenburg and O. El-maarri, New Insight into the Molecular Basis of Hemophilia A, International Journal of Hematology, vol.83, issue.2
DOI : 10.1532/IJH97.06012

B. Zhang, Bleeding due to disruption of a cargo-specific ER-to-Golgi transport complex, Nature Genetics, vol.34, issue.2, pp.220-225, 2003.
DOI : 10.1038/ng1153

G. M. Bhopale and R. K. Nanda, Blood coagulation factor VIII: An overview, Journal of Biosciences, vol.345, issue.6, pp.783-792, 2003.
DOI : 10.1007/BF02708439

URL : http://doi.org/10.1007/bf02708439

J. Oldenburg, Small deletion/insertion mutations within poly-A runs of the factor VIII gene mitigate the severe haemophilia A phenotype Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A, Thromb Haemost Nat Genet, vol.79, issue.53, pp.236-277, 1993.

K. Amano, The molecular basis for cross-reacting material-positive hemophilia A due to missense mutations within the A2-domain of factor VIII, Blood, issue.2, pp.91-538, 1998.

N. Yadav, Factor VIII Can Be Synthesized in Hemophilia A Mice Liver by Bone Marrow Progenitor Cell-Derived Hepatocytes and Sinusoidal Endothelial Cells, Stem Cells and Development, vol.21, issue.1, pp.110-130, 2012.
DOI : 10.1089/scd.2010.0569

G. A. Vehar, Structure of human factor VIII Expression of active human factor VIII from recombinant DNA clones, Nature Nature, vol.18, issue.59925992, pp.312-337, 1984.

R. J. Kaufman, Biosynthesis, assembly and secretion of coagulation factor VIII, Blood Coagul Fibrinolysis, vol.8, issue.2, pp.3-14, 1997.

J. B. Rosenberg, Intracellular trafficking of factor VIII to von Willebrand factor storage granules Platelets at work in primary hemostasis, J Clin Invest Blood Rev Best Pract Res Clin Obstet Gynaecol, vol.101, issue.223, pp.613-637, 1998.

E. W. Davie, K. Fujikawa, and W. Kisiel, The coagulation cascade: initiation, maintenance, and regulation, Biochemistry, vol.30, issue.43, pp.30-10363, 1991.
DOI : 10.1021/bi00107a001

K. Ovlisen, A. T. Kristensen, M. T. Field, R. A. , C. G. Rickard et al., In vivo models of haemophilia ??? status on current knowledge of clinical phenotypes and therapeutic interventions, Haemophilia, vol.1, issue.2, pp.248-59, 1946.
DOI : 10.1016/0300-9629(83)90061-0

J. B. Graham and J. A. Buckwalter, CANINE HEMOPHILIA: OBSERVATIONS ON THE COURSE, THE CLOTTING ANOMALY, AND THE EFFECT OF BLOOD TRANSFUSIONS, Journal of Experimental Medicine, vol.90, issue.2, pp.90-97, 1949.
DOI : 10.1084/jem.90.2.97

L. Bi, Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A, Nature Genetics, vol.64, issue.1, pp.119-140, 1995.
DOI : 10.1016/0092-8674(87)90646-5

L. Bi, Further characterization of factor VIII-deficient mice created by gene targeting: RNA and protein studies Animal models of hemophilia, Blood Prog Mol Biol Transl Sci, vol.88, issue.105, pp.151-209, 1996.

E. P. Mauser-bunschoten, D. E. Fransen-van-de-putte, and R. E. Schutgens, Co-morbidity in the ageing haemophilia patient: the down side of increased life expectancy, Haemophilia, vol.86, issue.Suppl 3, pp.853-63, 2009.
DOI : 10.1111/j.1365-2516.2009.01987.x

E. C. Rodriguez-merchan, Joint protection in haemophilia, Haemophilia, vol.12, issue.Suppl. 1, pp.1-23, 2011.
DOI : 10.1111/j.1365-2516.2011.02615.x

K. R. Viel, Inhibitors of Factor VIII in Black Patients with Hemophilia, New England Journal of Medicine, vol.360, issue.16, pp.1618-1645, 2009.
DOI : 10.1056/NEJMoa075760

S. Bjorkman, A. Folkesson, and S. Jonsson, Pharmacokinetics and dose requirements of factor VIII over the age range 3???74??years, European Journal of Clinical Pharmacology, vol.7, issue.Suppl. 1, pp.65-989, 2009.
DOI : 10.1007/s00228-009-0676-x

URL : https://hal.archives-ouvertes.fr/hal-00534970

A. Johnston, The Relevance of Factor VIII (FVIII) Pharmacokinetics to TDM and Hemophilia A Treatment: Is B Domain???Deleted FVIII Equivalent to Full-Length FVIII?, Therapeutic Drug Monitoring, vol.34, issue.1, pp.110-117, 2012.
DOI : 10.1097/FTD.0b013e318244fa5a

R. Mehta, R. Parameswaran, and A. D. Shapiro, An overview of the history, clinical practice concerns, comparative studies and strategies to optimize therapy of bypassing agents, Haemophilia, vol.63, issue.2, pp.54-61, 2006.
DOI : 10.1111/j.1365-2516.2005.01153.x

J. Oldenburg and A. Pavlova, Genetic risk factors for inhibitors to factors VIII and IX, Haemophilia, vol.77, issue.1, pp.15-22, 2006.
DOI : 10.1016/0167-5699(92)90107-I

A. Gringeri, Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group, Blood, vol.102, issue.7, pp.2358-63, 2003.
DOI : 10.1182/blood-2003-03-0941

B. Verbruggen, The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability, Thromb Haemost, vol.73, issue.2, pp.247-51, 1995.

C. A. Fulcher, S. De-graaf, T. S. Mahoney, and . Zimmerman, FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting, Blood, issue.5, pp.69-1475, 1987.

R. C. Aalberse, IgG4 as a blocking antibody, Clin Rev Allergy, vol.1, issue.2, pp.289-302, 1983.

B. C. Lubahn, Identification of a F.VIII epitope recognized by a human hemophilic inhibitor, Blood, vol.73, issue.2, pp.497-506, 1989.

D. Zhong, Some human inhibitor antibodies interfere with factor VIII binding to factor IX, Blood, vol.92, issue.1, pp.136-178, 1998.

M. Arai, D. Scandella, L. W. Hoyer, and M. , Molecular basis of factor VIII inhibition by human antibodies Antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine, J Clin Invest Thromb Haemost, vol.83, issue.63, pp.69-240, 1989.

E. L. Saenko, Slowed Release of Thrombin-cleaved Factor VIII from von Willebrand Factor by a Monoclonal and a Human Antibody Is a Novel Mechanism for Factor VIII Inhibition, Journal of Biological Chemistry, vol.271, issue.44, pp.271-27424, 1996.
DOI : 10.1074/jbc.271.44.27424

S. Lacroix-desmazes, Catalytic activity of antibodies against factor VIII in patients with hemophilia A, Nature Medicine, vol.5, issue.9, pp.1044-1051, 1999.
DOI : 10.1038/12483

S. Lacroix-desmazes, The Prevalence of Proteolytic Antibodies against Factor VIII in Hemophilia A, New England Journal of Medicine, vol.346, issue.9, pp.662-669, 2002.
DOI : 10.1056/NEJMoa011979

J. Qian, Inhibitor antibody development and T cell response to human factor VIII in murine hemophilia A, Thromb Haemost, vol.81, issue.2, pp.240-244, 1999.

J. F. Healey, The humoral response to human factor VIII in hemophilia A mice, Journal of Thrombosis and Haemostasis, vol.4, issue.Pt 1
DOI : 10.1111/j.1538-7836.2007.02373.x

J. Astermark, Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia The epidemiology of factor VIII inhibitors, Haemophilia C.R. Haemophilia, vol.12, issue.12 6, pp.23-31, 2006.

J. Oldenburg, HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII, Thromb Haemost, vol.77, issue.2, pp.238-280, 1997.

L. Moise, Effect of HLA DR epitope de-immunization of Factor VIII in vitro and in vivo, Clinical Immunology, vol.142, issue.3, pp.320-351, 2012.
DOI : 10.1016/j.clim.2011.11.010

J. Astermark, Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A, Blood, vol.108, issue.12, pp.3739-3784, 2006.
DOI : 10.1182/blood-2006-05-024711

J. Astermark, Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A, Blood, vol.107, issue.8, pp.3167-72, 2006.
DOI : 10.1182/blood-2005-09-3918

J. Astermark, Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A, Journal of Thrombosis and Haemostasis, vol.11, issue.2, pp.263-268, 2007.
DOI : 10.1111/j.1538-7836.2007.02290.x

L. M. Aledort, D. M. Dimichele, and S. , Inhibitors occur more frequently in African- American and Latino haemophiliacs Immunoprotective effect of von Willebrand factor towards therapeutic factor VIII in experimental haemophilia A. Haemophilia Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group Is the incidence and prevalence of inhibitors greater with recombinant products? No, Haemophilia N Engl J Med Blood Lusher, J.M. J Thromb Haemost, vol.4, issue.839 26, pp.248-54, 1993.

J. Goudemand, Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A, Blood, vol.107, issue.1, pp.46-51, 2006.
DOI : 10.1182/blood-2005-04-1371

S. C. Gouw, J. G. Van-der-bom, and H. , Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study, Blood, vol.109, issue.11, pp.4648-54, 2007.
DOI : 10.1182/blood-2006-11-056291

J. I. Lorenzo, Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age Age at first treatment and immune tolerance to factor VIII in severe hemophilia, Br J Haematol Thromb Haemost, vol.113, issue.653, pp.600-603, 2001.

S. C. Gouw, Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A Inhibitor development in a multitransfused patient with severe haemophilia A, J Thromb Haemost Thromb Haemost, vol.5, issue.821, pp.151-153, 1999.

M. Koestenberger, W. Raith, W. Muntean, M. , B. Leschnik et al., High titre inhibitor after continuous factor VIII administration for surgery in a young infant More on: mild hemophilia A and inhibitor development): p. 676; author reply 677 Dynamics of factor VIII interactions determine its immunologic fate in hemophilia A, Haemophilia J Thromb Haemost Blood, vol.6, issue.1122, pp.120-240, 2000.

D. Groot, A. S. , D. W. Scott, J. E. Brown, C. L. Carton et al., Immunogenicity of protein therapeutics The effect of naturally occurring antibodies to factor VIII on an immunoradiometric assay for factor VIII coagulant antigen. Observation on a cross-reacting material-positive (CRM+) hemophiliac with a factor VIII inhibit, Trends Immunol J Lab Clin Med, issue.111, pp.28-482, 1981.

P. R. Taylor, MACROPHAGE RECEPTORS AND IMMUNE RECOGNITION, Annual Review of Immunology, vol.23, issue.1, pp.901-945, 2005.
DOI : 10.1146/annurev.immunol.23.021704.115816

A. Navarrete, Splenic marginal zone antigen-presenting cells are critical for the primary allo-immune response to therapeutic factor VIII in hemophilia A, Journal of Thrombosis and Haemostasis, vol.78, issue.11, pp.1816-1839, 2009.
DOI : 10.1111/j.1538-7836.2009.03571.x

E. S. Trombetta and I. Mellman, CELL BIOLOGY OF ANTIGEN PROCESSING IN VITRO AND IN VIVO, Annual Review of Immunology, vol.23, issue.1, pp.975-1028, 2005.
DOI : 10.1146/annurev.immunol.22.012703.104538

J. Banchereau, Immunobiology of Dendritic Cells, Annual Review of Immunology, vol.18, issue.1, pp.767-811, 2000.
DOI : 10.1146/annurev.immunol.18.1.767

M. A. Nolte, Isolation of the intact white pulp. Quantitative and qualitative analysis of the cellular composition of the splenic compartments, European Journal of Immunology, vol.30, issue.2, pp.626-660, 2000.
DOI : 10.1002/1521-4141(200002)30:2<626::AID-IMMU626>3.0.CO;2-H

R. E. Mebius and G. Kraal, Structure and function of the spleen, Nature Reviews Immunology, vol.167, issue.8, pp.606-622, 2005.
DOI : 10.1093/emboj/19.9.2015

M. J. Manco-johnson, Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia, New England Journal of Medicine, vol.357, issue.6, pp.535-579, 2007.
DOI : 10.1056/NEJMoa067659

E. L. Saenko, Role of the Low Density Lipoprotein-related Protein Receptor in Mediation of Factor VIII Catabolism, Journal of Biological Chemistry, vol.274, issue.53, pp.274-37685, 1999.
DOI : 10.1074/jbc.274.53.37685

N. Bovenschen, The B domain of coagulation factor VIII interacts with the asialoglycoprotein receptor, Journal of Thrombosis and Haemostasis, vol.99, issue.6, pp.1257-65, 2005.
DOI : 10.1111/j.1538-7836.2005.01389.x

E. Herczenik, Uptake of blood coagulation factor VIII by dendritic cells is mediated via its C1 domain, Journal of Allergy and Clinical Immunology, vol.129, issue.2, pp.501-510, 2000.
DOI : 10.1016/j.jaci.2011.08.029

W. H. Leyva, A. P. Knutsen, and J. H. Joist, Disappearance of a High Response Factor VIII Inhibitor in a Hemophiliac with AIDS, American Journal of Clinical Pathology, vol.89, issue.3, pp.414-422, 1988.
DOI : 10.1093/ajcp/89.3.414

M. V. Ragni, F. A. Bontempo, and J. H. Lewis, Disappearance of inhibitor to factor VIII in HIV-infected hemophiliacs with progression to AIDS or severe ARC, Transfusion, vol.29, issue.5, pp.29-447, 1989.
DOI : 10.1046/j.1537-2995.1989.29589284147.x

N. Misra, Restricted BV gene usage by Factor VIII-reactive CD4+ T cells in inhibitor-positive patients with severe hemophilia A, Thrombosis and Haemostasis, issue.5, pp.90-813, 2003.
DOI : 10.1160/TH03-05-0300

S. Quaratino, L. P. Duddy, and M. Londei, Fully competent dendritic cells as inducers of T cell anergy in autoimmunity, Proc Natl Acad Sci, issue.20, pp.97-10911, 2000.

A. Corthay, A Three-cell Model for Activation of Na??ve T Helper Cells, Scandinavian Journal of Immunology, vol.60, issue.Pt 1, pp.93-99, 2006.
DOI : 10.1111/j.1365-3083.2006.01782.x

J. Qian, Prevention and treatment of factor VIII inhibitors in murine hemophilia A, Blood, vol.95, issue.4, pp.1324-1333, 2000.

M. T. Reding, Distribution of Th1-and Th2-induced anti-factor VIII IgG subclasses in congenital and acquired hemophilia patients, Thromb Haemost, vol.88, issue.4, pp.568-75, 2002.

C. Hausl, Long-term persistence of anti-factor VIII antibody-secreting cells in hemophilic mice after treatment with human factor VIII, Thromb Haemost, vol.87, issue.5, pp.840-845, 2002.

C. Hausl, Preventing restimulation of memory B cells in hemophilia A: a potential new strategy for the treatment of antibody-dependent immune disorders, 1514. 96. Bretscher, P. and M. Cohn, pp.115-137, 1929.
DOI : 10.1182/blood-2003-07-2456

K. J. Lafferty and A. J. Cunningham, A NEW ANALYSIS OF ALLOGENEIC INTERACTIONS, Australian Journal of Experimental Biology and Medical Science, vol.131, issue.1, pp.27-42, 1975.
DOI : 10.1073/pnas.68.12.3031

C. A. Janeway and . Jr, Approaching the Asymptote? Evolution and Revolution in Immunology, Cold Spring Harbor Symposia on Quantitative Biology, vol.54, issue.0, pp.1-13, 1989.
DOI : 10.1101/SQB.1989.054.01.003

P. Matzinger, Tolerance, Danger, and the Extended Family, Annual Review of Immunology, vol.12, issue.1, pp.991-1045, 1994.
DOI : 10.1146/annurev.iy.12.040194.005015

P. Matzinger, The Danger Model: A Renewed Sense of Self, Science, vol.296, issue.5566, pp.296-301, 2002.
DOI : 10.1126/science.1071059

S. Y. Seong and P. Matzinger, Opinion: Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses, Nature Reviews Immunology, vol.29, issue.6, pp.469-78, 2004.
DOI : 10.1126/science.285.5430.1058

S. Sirisinha, Insight into the mechanisms regulating immune homeostasis in health and disease, Asian Pac J Allergy Immunol, vol.29, issue.1, pp.1-14, 2011.

D. Gregorio, E. , U. D. Oro, and A. Wack, Immunology of TLR-independent vaccine adjuvants, Current Opinion in Immunology, vol.21, issue.3, pp.339-384, 2009.
DOI : 10.1016/j.coi.2009.05.003

K. Pfistershammer, Recombinant factor VIII and factor VIII-von Willebrand factor complex do not present danger signals for human dendritic cells, Thrombosis and Haemostasis, issue.3, pp.96-309, 2006.
DOI : 10.1160/TH05-11-0729

P. Scaffidi, T. Misteli, and M. E. Bianchi, Release of chromatin protein HMGB1 by necrotic cells triggers inflammation, Nature, issue.6894, pp.418-191, 2002.

F. J. Quintana and I. R. Cohen, Heat Shock Proteins as Endogenous Adjuvants in Sterile and Septic Inflammation, The Journal of Immunology, vol.175, issue.5, pp.2777-82, 2005.
DOI : 10.4049/jimmunol.175.5.2777

M. J. Bours, Adenosine 5???-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation, Pharmacology & Therapeutics, vol.112, issue.2, pp.358-404, 2006.
DOI : 10.1016/j.pharmthera.2005.04.013

H. Kono, Uric acid promotes an acute inflammatory response to sterile cell death in mice, Journal of Clinical Investigation, vol.120, issue.6, pp.1939-1988, 2010.
DOI : 10.1172/JCI40124DS1

A. Babelova, Biglycan, a Danger Signal That Activates the NLRP3 Inflammasome via Toll-like and P2X Receptors, Journal of Biological Chemistry, vol.284, issue.36, pp.284-24035, 2009.
DOI : 10.1074/jbc.M109.014266

J. J. Oppenheim, Alarmins Initiate Host Defense, Adv Exp Med Biol, vol.601, pp.185-94, 2007.
DOI : 10.1007/978-0-387-72005-0_19

G. Y. Chen and G. Nunez, Sterile inflammation: sensing and reacting to damage, Nature Reviews Immunology, vol.464, issue.12, pp.826-863, 2010.
DOI : 10.1038/nri2873

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3114424

S. Raut, Modification of factor VIII in therapeutic concentrates after virus inactivation by solvent-detergent and pasteurisation, Thromb Haemost, vol.80, issue.4, pp.624-655, 1998.

T. Kawai and S. Akira, The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors, Nature Immunology, vol.1799, issue.5, pp.373-84, 2010.
DOI : 10.1126/science.1179050

C. V. Prowse and I. R. Macgregor, Neoantigens and antibodies to factor VIII, Blood Reviews, vol.12, issue.2, pp.99-105, 1998.
DOI : 10.1016/S0268-960X(98)90021-2

K. Takeda and S. Akira, Toll-like receptors, Curr Protoc Immunol, vol.14, issue.14, p.12, 2007.
DOI : 10.1002/0471142735.im1412s109

K. Kurnik, New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development, Haemophilia, vol.110, issue.Suppl. 2, pp.256-62, 2010.
DOI : 10.1111/j.1365-2516.2009.02122.x

N. G. Abraham and A. Kappas, Pharmacological and Clinical Aspects of Heme Oxygenase, Pharmacological Reviews, vol.60, issue.1, pp.79-127, 2008.
DOI : 10.1124/pr.107.07104

S. W. Ryter, J. Alam, and A. M. Choi, Heme Oxygenase-1/Carbon Monoxide: From Basic Science to Therapeutic Applications, Physiological Reviews, vol.86, issue.2, pp.583-650, 2006.
DOI : 10.1152/physrev.00011.2005

F. A. Wagener, The heme-heme oxygenase system: a molecular switch in wound healing, Blood, vol.102, issue.2, pp.521-529, 2003.
DOI : 10.1182/blood-2002-07-2248

J. D. Dimitrov, Induction of heme oxygenase-1 in factor VIII-deficient mice reduces the immune response to therapeutic factor VIII, Blood, vol.115, issue.13, pp.115-2682, 2010.
DOI : 10.1182/blood-2009-04-216408

J. Dawes, High Molecular Weight Aggregate Content of Heated and Unheated Factor VIII Products Determined by Fast-Protein Liquid Chromatography, Vox Sanguinis, vol.49, issue.1, pp.30-34, 1990.
DOI : 10.1111/j.1423-0410.1990.tb02051.x

A. S. Rosenberg, Effects of protein aggregates: An immunologic perspective, The AAPS Journal, vol.8, issue.3, pp.501-508, 2006.
DOI : 10.1208/aapsj080359

V. S. Purohit, C. R. Middaugh, and S. V. Balasubramanian, Influence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A mice, Journal of Pharmaceutical Sciences, vol.95, issue.2, pp.95-358, 2006.
DOI : 10.1002/jps.20529

P. Gaitonde, Downregulation of CD40 Signal and Induction of TGF-?? by Phosphatidylinositol Mediates Reduction in Immunogenicity Against Recombinant Human Factor VIII, Journal of Pharmaceutical Sciences, vol.101, issue.1, pp.48-55, 2012.
DOI : 10.1002/jps.22746

S. T. Smiley, J. A. King, and W. W. Hancock, Fibrinogen Stimulates Macrophage Chemokine Secretion Through Toll-Like Receptor 4, The Journal of Immunology, vol.167, issue.5, pp.2887-94, 2001.
DOI : 10.4049/jimmunol.167.5.2887

Y. Dargaud, Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B, Thrombosis and Haemostasis, vol.93, issue.3, pp.475-80, 2005.
DOI : 10.1160/TH04-10-0706

J. Skupsky, A role for thrombin in the initiation of the immune response to therapeutic factor VIII, Blood, vol.114, issue.21, pp.4741-4749, 2009.
DOI : 10.1182/blood-2008-10-186452

D. Bluteau, Regulation of megakaryocyte maturation and platelet formation, Journal of Thrombosis and Haemostasis, vol.113, issue.Suppl. 1, pp.227-261, 2009.
DOI : 10.1111/j.1538-7836.2009.03398.x

J. E. Italiano and . Jr, Blood Platelets Are Assembled Principally at the Ends of Proplatelet Processes Produced by Differentiated Megakaryocytes, The Journal of Cell Biology, vol.30, issue.6, pp.1299-312, 1999.
DOI : 10.1083/jcb.99.2.390

M. Jandrot-perrus and P. Nurden, Des fonctions plaquettaires aux implications th??rapeutiques, La Revue de M??decine Interne, vol.31, issue.3, pp.319-342, 2010.
DOI : 10.1016/j.revmed.2010.09.020

M. M. Denis, Escaping the Nuclear Confines: Signal-Dependent Pre-mRNA Splicing in Anucleate Platelets, Cell, vol.122, issue.3, pp.379-91, 2005.
DOI : 10.1016/j.cell.2005.06.015

S. Lindemann, Activated platelets mediate inflammatory signaling by regulated interleukin 1?? synthesis, The Journal of Cell Biology, vol.87, issue.3, pp.485-90, 2001.
DOI : 10.1073/pnas.95.10.5556

S. Sehgal and B. Storrie, Evidence that differential packaging of the major platelet granule proteins von Willebrand factor and fibrinogen can support their differential release, Journal of Thrombosis and Haemostasis, vol.72, issue.10, pp.2009-2025, 2007.
DOI : 10.1038/nrd2115

J. E. Italiano and . Jr, Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet ?? granules and differentially released, Blood, vol.111, issue.3, pp.1227-1260, 2008.
DOI : 10.1182/blood-2007-09-113837

J. A. Coppinger, Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions, Blood, vol.103, issue.6, pp.2096-104, 2004.
DOI : 10.1182/blood-2003-08-2804

R. Grozovsky, K. M. Hoffmeister, and H. Falet, Novel clearance mechanisms of platelets, Current Opinion in Hematology, vol.17, issue.6, pp.585-594, 2010.
DOI : 10.1097/MOH.0b013e32833e7561

P. S. Hartley, Platelet senescence and death, Clin Lab, vol.53, issue.3-4, pp.157-66, 2007.

Z. M. Ruggeri, Platelet adhesion under flow. Microcirculation, pp.58-83, 2009.

S. P. Jackson, W. S. Nesbitt, and S. Kulkarni, Signaling events underlying thrombus formation, Journal of Thrombosis and Haemostasis, vol.14, issue.7, pp.1602-1614, 2003.
DOI : 10.1073/pnas.96.5.2311

S. J. Shattil, H. Kashiwagi, and N. Pampori, Integrin signaling: the platelet paradigm, Blood, issue.8, pp.91-2645, 1998.

C. Antoniades, Platelet Activation in Atherogenesis Associated with Low-Grade Inflammation, Inflammation & Allergy - Drug Targets, vol.9, issue.5, pp.334-379, 2010.
DOI : 10.2174/187152810793938035

E. Boilard, Platelets Amplify Inflammation in Arthritis via Collagen-Dependent Microparticle Production, Science, vol.327, issue.5965, pp.580-583, 2010.
DOI : 10.1126/science.1181928

C. E. Collins, Platelets circulate in an activated state in inflammatory bowel disease, Gastroenterology, vol.106, issue.4, pp.840-845, 1994.
DOI : 10.1016/0016-5085(94)90741-2

A. Solanilla, Platelet-associated CD154 in immune thrombocytopenic purpura, Blood, vol.105, issue.1, pp.215-223, 2005.
DOI : 10.1182/blood-2003-07-2367

URL : https://hal.archives-ouvertes.fr/hal-00019938

S. I. Rosenfeld, Human platelet Fc receptor for immunoglobulin G. Identification as a 40,000-molecular-weight membrane protein shared by monocytes., Journal of Clinical Investigation, vol.76, issue.6
DOI : 10.1172/JCI112242

M. Joseph, A new function for platelets: IgE-dependent killing of schistosomes, Nature, vol.52, issue.5920, pp.810-812, 1983.
DOI : 10.1038/303810a0

D. Bout, Rat resistance to schistosomiasis: platelet-mediated cytotoxicity induced by C-reactive protein, Science, vol.231, issue.4734, pp.231-153, 1986.
DOI : 10.1126/science.3079916

L. J. Cosgrove, CR3 receptor on platelets and its role in the prostaglandin metabolic pathway, Immunology and Cell Biology, vol.134, issue.6, pp.65-453, 1987.
DOI : 10.1038/icb.1987.54

K. J. Clemetson, Functional expression of CCR1, CCR3, CCR4, and CXCR4 chemokine receptors on human platelets, Blood, issue.13, pp.96-4046, 2000.

V. Pancre, Interleukin-6 is the main mediator of the interaction between monocytes and platelets in the killing of Schistosoma mansoni, Eur Cytokine Netw, vol.1, issue.1, pp.15-24, 1990.

M. R. Yeaman, Bacterial???platelet interactions: virulence meets host defense, Future Microbiology, vol.5, issue.3, pp.471-506, 2010.
DOI : 10.2217/fmb.09.112

F. Cognasse, Evidence of Toll-like receptor molecules on human platelets, Immunology and Cell Biology, vol.171, issue.2, pp.196-204, 2005.
DOI : 10.1128/IAI.70.12.6524-6533.2002

R. Shiraki, Expression of Toll-like receptors on human platelets, Thrombosis Research, vol.113, issue.6, pp.379-85, 2004.
DOI : 10.1016/j.thromres.2004.03.023

R. Aslam, Platelet Toll-like receptor expression modulates lipopolysaccharide-induced thrombocytopenia and tumor necrosis factor-?? production in vivo, Blood, vol.107, issue.2, pp.637-678, 2006.
DOI : 10.1182/blood-2005-06-2202

S. L. Spinelli, Platelets and Megakaryocytes Contain Functional Nuclear Factor-??B, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.30, issue.3, pp.591-599, 2010.
DOI : 10.1161/ATVBAHA.109.197343

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2853005

P. Andre, Platelet-Derived CD40L: The Switch-Hitting Player of Cardiovascular Disease, Circulation, vol.106, issue.8, pp.896-905, 2002.
DOI : 10.1161/01.CIR.0000028962.04520.01

C. M. Hawrylowicz, G. L. Howells, and M. Feldmann, Platelet-derived interleukin 1 induces human endothelial adhesion molecule expression and cytokine production, Journal of Experimental Medicine, vol.174, issue.4, pp.785-90, 1991.
DOI : 10.1084/jem.174.4.785

C. Urbich, CD40 Ligand Inhibits Endothelial Cell Migration by Increasing Production of Endothelial Reactive Oxygen Species, Circulation, vol.106, issue.8, pp.981-987, 2002.
DOI : 10.1161/01.CIR.0000027107.54614.1A

M. Gawaz, H. Langer, and A. E. May, Platelets in inflammation and atherogenesis, Journal of Clinical Investigation, vol.115, issue.12, pp.3378-84, 2005.
DOI : 10.1172/JCI27196

C. A. Petti, V. G. Fowler, and J. , Staphylococcus aureus bacteremia and endocarditis, Cardiology Clinics, vol.21, issue.2, pp.219-252, 2003.
DOI : 10.1016/S0733-8651(03)00030-4

M. Levi, Infection and inflammation and the coagulation system, Cardiovascular Research, vol.60, issue.1, pp.26-39, 2003.
DOI : 10.1016/S0008-6363(02)00857-X

S. W. Kerrigan, A role for glycoprotein Ib in Streptococcus sanguis-induced platelet aggregation, Blood, vol.100, issue.2, pp.509-525, 2002.
DOI : 10.1182/blood.V100.2.509

O. 'brien and L. , Multiple mechanisms for the activation of human platelet aggregation by Staphylococcus aureus: roles for the clumping factors ClfA and ClfB, the serine-aspartate repeat protein SdrE and protein A, Mol Microbiol, vol.44, issue.4, pp.1033-1077, 2002.

H. Kalvegren, M. Majeed, and T. Bengtsson, Chlamydia pneumoniae Binds to Platelets and Triggers P-Selectin Expression and Aggregation: A Causal Role in Cardiovascular Disease?, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.23, issue.9, pp.1677-83, 2003.
DOI : 10.1161/01.ATV.0000084810.52464.D5

A. L. Copley, B. Maupin, and T. Balea, The agglutinant and adhesive behaviour of isolated human and rabbit platelets in contact with various strains of mycobacteria

T. Youssefian, Host defense role of platelets: engulfment of HIV and Staphylococcus aureus occurs in a specific subcellular compartment and is enhanced by platelet activation, Blood, vol.99, issue.11, pp.99-4021, 2002.
DOI : 10.1182/blood-2001-12-0191

H. Terada, Interaction of influenza virus with blood platelets, Blood, vol.28, issue.2, pp.213-241, 1966.

T. Bik, I. Sarov, and A. Livne, Interaction between vaccinia virus and human blood platelets, Blood, vol.59, issue.3, pp.482-489, 1982.

M. R. Yeaman, The Role of Platelets in Antimicrobial Host Defense, Clinical Infectious Diseases, vol.25, issue.5, pp.951-68, 1997.
DOI : 10.1086/516120

P. A. Maisch and R. A. Calderone, Role of surface mannan in the adherence of Candida albicans to fibrin-platelet clots formed in vitro, Infect Immun, vol.32, issue.1, pp.92-99, 1981.

L. Christin, Human platelets damage Aspergillus fumigatus hyphae and may supplement killing by neutrophils, Infect Immun, vol.66, issue.3, pp.1181-1190, 1998.

E. C. Yong, Human platelet-mediated cytotoxicity against Toxoplasma gondii: role of thromboxane, Journal of Experimental Medicine, vol.173, issue.1, pp.65-78, 1991.
DOI : 10.1084/jem.173.1.65

F. Peyron, Plasmodium falciparum growth inhibition by human platelets in vitro, Parasitology, vol.46, issue.03, pp.317-339, 1989.
DOI : 10.1084/jem.156.4.1210

A. Verschoor, A platelet-mediated system for shuttling blood-borne bacteria to CD8alpha+ dendritic cells depends on glycoprotein GPIb and complement C3, Nat Immunol, issue.12, pp.12-1194, 2011.

L. M. Chapman, Platelets Present Antigen in the Context of MHC Class I, The Journal of Immunology, vol.189, issue.2, 2012.
DOI : 10.4049/jimmunol.1200580

E. R. Van-bladel, Up-regulation of platelet activation in hemophilia A, Haematologica, vol.96, issue.6, pp.888-95, 2011.
DOI : 10.3324/haematol.2011.042663

M. Grunewald, Absence of compensatory platelet activation in patients with severe haemophilia, but evidence for a platelet collagen-activation defect, Platelets, vol.13, issue.8, pp.13-451, 2002.
DOI : 10.1080/0953710021000059422

S. R. Amith, The role of NEU1sialidase in toll-like receptor activation, in Department of Microbiology and Immunology, p.299, 2009.

K. Jobi, Redox regulation of human protease-activated receptor-2 by activated factor X, Free Radical Biology and Medicine, vol.51, issue.9, pp.1758-64, 2011.
DOI : 10.1016/j.freeradbiomed.2011.08.003

W. Ruf, A. Dorfleutner, and M. Riewald, Specificity of coagulation factor signaling, Journal of Thrombosis and Haemostasis, vol.286, issue.7, pp.1495-503, 2003.
DOI : 10.1083/jcb.140.5.1241

B. D. Elzey, Platelet-Mediated Modulation of Adaptive Immunity, Immunity, vol.19, issue.1, pp.9-19, 2003.
DOI : 10.1016/S1074-7613(03)00177-8

G. Davi and C. Patrono, Platelet Activation and Atherothrombosis, New England Journal of Medicine, vol.357, issue.24, pp.2482-94, 2007.
DOI : 10.1056/NEJMra071014

T. M. Ross, C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge, Nature Immunology, vol.1, issue.2, pp.127-158, 2000.
DOI : 10.1038/77802

F. Yarovinsky, Toll-like Receptor Recognition Regulates Immunodominance in an Antimicrobial CD4+ T Cell Response, Immunity, vol.25, issue.4, pp.655-64, 2006.
DOI : 10.1016/j.immuni.2006.07.015

S. Burgdorf, Distinct Pathways of Antigen Uptake and Intracellular Routing in CD4 and CD8 T Cell Activation, Science, vol.316, issue.5824, pp.316-612, 2007.
DOI : 10.1126/science.1137971

D. Dudziak, Differential Antigen Processing by Dendritic Cell Subsets in Vivo, Science, vol.315, issue.5808, pp.315-107, 2007.
DOI : 10.1126/science.1136080

S. I. Gringhuis, Dectin-1 directs T helper cell differentiation by controlling noncanonical NF-??B activation through Raf-1 and Syk, Nature Immunology, vol.175, issue.2, pp.203-216, 2009.
DOI : 10.1128/JVI.78.4.1665-1674.2004

S. R. Amith, Detection of Neu1 Sialidase Activity in Regulating TOLL-like Receptor Activation, Journal of Visualized Experiments, issue.43, p.2010
DOI : 10.3791/2142

H. Hua, Phenotypic and functional maturation of murine dendritic cells (DCs) induced by purified Glycyrrhizin (GL), International Immunopharmacology, vol.12, issue.3, pp.518-543, 2012.
DOI : 10.1016/j.intimp.2012.01.006

A. Peng, R. M. Straubinger, and S. V. Balu-iyer, Phosphatidylinositol Containing Lipidic Particles Reduces Immunogenicity and Catabolism of Factor VIII in Hemophilia A Mice, The AAPS Journal, vol.12, issue.3, pp.473-81, 2010.
DOI : 10.1208/s12248-010-9207-z

J. I. Borissoff, H. M. Spronk, and H. Cate, The hemostatic system as a modulator of atherosclerosis, N Engl J Med, issue.18, pp.364-1746, 2011.

N. Semeraro, Sepsis, thrombosis and organ dysfunction, Thrombosis Research, vol.129, issue.3, pp.290-295, 2012.
DOI : 10.1016/j.thromres.2011.10.013

J. G. Olinde, Persantine attenuates hemorrhagic shock-induced P-selectin expression, Am Surg, vol.66, issue.12, pp.1093-1100, 2000.

P. Molho, Epidemiological survey of the orthopaedic status of severe haemophilia A and B patients in France, Haemophilia, vol.2, issue.1, pp.23-32, 2000.
DOI : 10.1046/j.1365-2796.1997.130135000.x

J. Oldenburg, O. El-maarri, and R. Schwaab, Inhibitor development in correlation to factor VIII genotypes, Haemophilia, vol.89, issue.2, pp.23-32, 2002.
DOI : 10.1074/jbc.270.24.14505

C. P. Hodgkinson, K. Patel, and S. Ye, Functional Toll-like receptor 4 mutations modulate the response to fibrinogen, Thrombosis and Haemostasis, vol.100, issue.2, pp.301-308, 2008.
DOI : 10.1160/TH08-03-0179

D. Davalos and K. Akassoglou, Fibrinogen as a key regulator of inflammation in disease, Seminars in Immunopathology, vol.472, issue.7341, pp.43-62, 2012.
DOI : 10.1007/s00281-011-0290-8

G. Auerswald, C. Bidlingmaier, and K. Kurnik, Early prophylaxis/FVIII tolerization regimen that avoids immunological danger signals is still effective in minimizing FVIII inhibitor developments in previously untreated patients - long-term follow-up and continuing experience, Haemophilia, vol.16, issue.Suppl 1, pp.18-20, 2012.
DOI : 10.1111/j.1365-2516.2011.02659.x

D. M. Lundvig, S. Immenschuh, and F. A. Wagener, Heme Oxygenase, Inflammation, and Fibrosis: The Good, the Bad, and the Ugly?, Frontiers in Pharmacology, vol.3, issue.3, p.81, 2012.
DOI : 10.3389/fphar.2012.00081

D. A. Wink, Nitric oxide and redox mechanisms in the immune response, Journal of Leukocyte Biology, vol.89, issue.6, pp.873-91, 2011.
DOI : 10.1189/jlb.1010550

J. Hirsh, Oral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range, Chest, vol.119, issue.1, pp.8-21, 2001.
DOI : 10.1378/chest.119.1_suppl.8S

S. R. Macfarlane, Proteinase-activated receptors, Pharmacol Rev, vol.53, issue.2, pp.245-82, 2001.

S. R. Coughlin, Thrombin signalling and protease-activated receptors, Nature, issue.6801, pp.407-258, 2000.

Y. Park, Effect of PAR2 in regulating TNF-?? and NAD(P)H oxidase in coronary arterioles in type 2 diabetic mice, Basic Research in Cardiology, vol.297, issue.1, pp.111-134, 2011.
DOI : 10.1007/s00395-010-0129-9

H. Kataoka, Protease-activated receptors 1 and 4 mediate thrombin signaling in endothelial cells, Blood, vol.102, issue.9, pp.3224-3255, 2003.
DOI : 10.1182/blood-2003-04-1130

M. Nakanishi-matsui, PAR3 is a cofactor for PAR4 activation by thrombin, Nature, vol.404, issue.6778, pp.609-622, 2000.

J. Jin and S. P. Kunapuli, Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation, Proceedings of the National Academy of Sciences, vol.95, issue.14, pp.95-8070, 1998.
DOI : 10.1073/pnas.95.14.8070

R. A. Kroczek, Defective Expression of CD40 Ligand on T Cells Causes "X-Linked Immunodeficiency with Hyper-IgM (HIGM1)", Immunological Reviews, vol.146, issue.1, pp.39-59, 1994.
DOI : 10.1146/annurev.immunol.10.1.411

J. Qian, Role of CD154 in the secondary immune response: the reduction of pre-existing splenic germinal centers and anti-factor VIII inhibitor titer, European Journal of Immunology, vol.30, issue.9, pp.2548-54, 2000.
DOI : 10.1002/1521-4141(200009)30:9<2548::AID-IMMU2548>3.0.CO;2-H

B. M. Reipert, Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance, Thromb Haemost, vol.86, issue.6, pp.1345-52, 2001.

G. Rossi, J. Sarkar, and D. Scandella, Long-term induction of immune tolerance after blockade of CD40-CD40L interaction in a mouse model of hemophilia A, Blood, vol.97, issue.9, pp.97-2750, 2001.
DOI : 10.1182/blood.V97.9.2750

B. M. Ewenstein, Inhibition of CD40 ligand (CD154) in the treatment of factor VIII inhibitors, Haematologica, vol.85, pp.35-44, 2000.

C. Caux, Activation of human dendritic cells through CD40 cross-linking, Journal of Experimental Medicine, vol.180, issue.4, pp.1263-72, 1994.
DOI : 10.1084/jem.180.4.1263

R. A. Fox, E. J. Neufeld, and C. M. Bennett, Rituximab for adolescents with haemophilia and high titre inhibitors, Haemophilia, vol.10, issue.3, pp.218-240, 2006.
DOI : 10.1111/j.1365-2516.2005.01170.x

T. T. Biss, M. R. Velangi, and J. P. Hanley, Failure of rituximab to induce immune tolerance in a boy with severe haemophilia A and an alloimmune factor VIII antibody: a case report and review of the literature, Haemophilia, vol.79, issue.1, pp.12-280, 2006.
DOI : 10.1182/blood-2003-11-4075

M. Moschovi, Rituximab in the treatment of high responding inhibitors in severe haemophilia A, Haemophilia, vol.96, issue.1, pp.95-104, 2006.
DOI : 10.1046/j.1365-2516.2003.00783.x

C. Kessel, Humoral immune responsiveness to a defined epitope on factor VIII before and after B cell ablation with rituximab, Molecular Immunology, vol.46, issue.1, pp.8-15, 2008.
DOI : 10.1016/j.molimm.2008.06.015

B. Waters, Anti-CD3 prevents factor VIII inhibitor development in hemophilia A mice by a regulatory CD4+CD25+-dependent mechanism and by shifting cytokine production to favor a Th1 response, Blood, vol.113, issue.1, pp.193-203, 2009.
DOI : 10.1182/blood-2008-04-151597

P. J. Lenting, The Light Chain of Factor VIII Comprises a Binding Site for Low Density Lipoprotein Receptor-related Protein, Journal of Biological Chemistry, vol.274, issue.34, pp.274-23734, 1999.
DOI : 10.1074/jbc.274.34.23734

J. N. Pegon, Factor VIII and von Willebrand factor are ligands for the carbohydrate-receptor Siglec-5, Haematologica, vol.97, issue.12, 2012.
DOI : 10.3324/haematol.2012.063297

S. Dasgupta, Factor VIII bypasses CD91/LRP for endocytosis by dendritic cells leading to T-cell activation, Haematologica, vol.93, issue.1, pp.83-92, 2008.
DOI : 10.3324/haematol.11535

Y. Repesse, Mannose-sensitive receptors mediate the uptake of factor VIII therapeutics by human dendritic cells, Journal of Allergy and Clinical Immunology, vol.129, issue.4, pp.1172-1175, 2012.
DOI : 10.1016/j.jaci.2012.01.048